BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 38104484)

  • 1. M
    Liu X; Li P; Huang Y; Li H; Liu X; Du Y; Lin X; Chen D; Liu H; Zhou Y
    Redox Biol; 2024 Feb; 69():102993. PubMed ID: 38104484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of a novel mechanism for reversal of doxorubicin-induced chemotherapy resistance by TXNIP in triple-negative breast cancer via promoting reactive oxygen-mediated DNA damage.
    Chen Y; Feng X; Yuan Y; Jiang J; Zhang P; Zhang B
    Cell Death Dis; 2022 Apr; 13(4):338. PubMed ID: 35414060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ALKBH5-Mediated m6A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer.
    Liu H; Lyu H; Jiang G; Chen D; Ruan S; Liu S; Zhou L; Yang M; Zeng S; He Z; Wang H; Li H; Zheng G; Liu B
    Cancer Res; 2022 Nov; 82(21):3974-3986. PubMed ID: 36069931
    [TBL] [Abstract][Full Text] [Related]  

  • 4. ALKBH5-mediated m6A-demethylation of USP1 regulated T-cell acute lymphoblastic leukemia cell glucocorticoid resistance by Aurora B.
    Gong H; Liu L; Cui L; Ma H; Shen L
    Mol Carcinog; 2021 Sep; 60(9):644-657. PubMed ID: 34169564
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Post-translational modification of RNA m6A demethylase ALKBH5 regulates ROS-induced DNA damage response.
    Yu F; Wei J; Cui X; Yu C; Ni W; Bungert J; Wu L; He C; Qian Z
    Nucleic Acids Res; 2021 Jun; 49(10):5779-5797. PubMed ID: 34048572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DDX3 modulates cisplatin resistance in OSCC through ALKBH5-mediated m
    Shriwas O; Priyadarshini M; Samal SK; Rath R; Panda S; Das Majumdar SK; Muduly DK; Botlagunta M; Dash R
    Apoptosis; 2020 Apr; 25(3-4):233-246. PubMed ID: 31974865
    [TBL] [Abstract][Full Text] [Related]  

  • 8. m
    Nagaki Y; Motoyama S; Yamaguchi T; Hoshizaki M; Sato Y; Sato T; Koizumi Y; Wakita A; Kawakita Y; Imai K; Nanjo H; Watanabe H; Imai Y; Minamiya Y; Kuba K
    Genes Cells; 2020 Aug; 25(8):547-561. PubMed ID: 32449584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ALKBH5-mediated m
    Hao L; Yin J; Yang H; Li C; Zhu L; Liu L; Zhong J
    Aging (Albany NY); 2021 Jan; 13(3):4045-4062. PubMed ID: 33428593
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioactive peptide inhibits acute myeloid leukemia cell proliferation by downregulating ALKBH5-mediated m
    Zhang L; Su X
    Cell Oncol (Dordr); 2022 Jun; 45(3):355-365. PubMed ID: 35579750
    [TBL] [Abstract][Full Text] [Related]  

  • 11. N6-methyladenosine demethylase ALKBH5 suppresses colorectal cancer progression potentially by decreasing PHF20 mRNA methylation.
    Zhang Z; Wang L; Zhao L; Wang Q; Yang C; Zhang M; Wang B; Jiang K; Ye Y; Wang S; Shen Z
    Clin Transl Med; 2022 Aug; 12(8):e940. PubMed ID: 35979628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Substance P Receptor Signaling Mediates Doxorubicin-Induced Cardiomyocyte Apoptosis and Triple-Negative Breast Cancer Chemoresistance.
    Robinson P; Kasembeli M; Bharadwaj U; Engineer N; Eckols KT; Tweardy DJ
    Biomed Res Int; 2016; 2016():1959270. PubMed ID: 26981525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ALKBH5 Promotes Multiple Myeloma Tumorigenicity through inducing m
    Yu T; Yao L; Yin H; Teng Y; Hong M; Wu Q
    Int J Biol Sci; 2022; 18(6):2235-2248. PubMed ID: 35414790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ALKBH5 regulates paclitaxel resistance in NSCLC via inhibiting CEMIP-mediated EMT.
    Gao L; Qiao L; Li Y; Jia L; Cui W; Yang J; Wu C; Wang L
    Toxicol Appl Pharmacol; 2024 Feb; 483():116807. PubMed ID: 38199493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N
    Zhu Z; Qian Q; Zhao X; Ma L; Chen P
    Gene; 2020 Mar; 731():144348. PubMed ID: 31927006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual-target MDM2/MDMX inhibitor increases the sensitization of doxorubicin and inhibits migration and invasion abilities of triple-negative breast cancer cells through activation of TAB1/TAK1/p38 MAPK pathway.
    Fan Y; Li M; Ma K; Hu Y; Jing J; Shi Y; Li E; Dong D
    Cancer Biol Ther; 2019; 20(5):617-632. PubMed ID: 30462562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Promoting axon regeneration by inhibiting RNA N6-methyladenosine demethylase ALKBH5.
    Wang D; Zheng T; Zhou S; Liu M; Liu Y; Gu X; Mao S; Yu B
    Elife; 2023 Aug; 12():. PubMed ID: 37535403
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RNA demethylase ALKBH5 in cancer: from mechanisms to therapeutic potential.
    Qu J; Yan H; Hou Y; Cao W; Liu Y; Zhang E; He J; Cai Z
    J Hematol Oncol; 2022 Jan; 15(1):8. PubMed ID: 35063010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EGFR promotes ALKBH5 nuclear retention to attenuate N6-methyladenosine and protect against ferroptosis in glioblastoma.
    Lv D; Zhong C; Dixit D; Yang K; Wu Q; Godugu B; Prager BC; Zhao G; Wang X; Xie Q; Bao S; He C; Heiland DH; Rosenfeld MG; Rich JN
    Mol Cell; 2023 Dec; 83(23):4334-4351.e7. PubMed ID: 37979586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exosome-sheathed porous silica nanoparticle-mediated co-delivery of 3,3'-diindolylmethane and doxorubicin attenuates cancer stem cell-driven EMT in triple negative breast cancer.
    Sarkar R; Biswas S; Ghosh R; Samanta P; Pakhira S; Mondal M; Dutta Gupta Y; Bhandary S; Saha P; Bhowmik A; Hajra S
    J Nanobiotechnology; 2024 May; 22(1):285. PubMed ID: 38796426
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.